These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38975713)

  • 1. Radioactive Hydroxyapatite Microspheres Empower Sustainable
    Xu P; Gu Y; Li C; Shen J; Cheng X; Zhang LW; Wang Y; Wang Y
    ACS Nano; 2024 Jul; 18(28):18425-18443. PubMed ID: 38975713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
    Jagodinsky JC; Bates AM; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarty I; Nystuen EJ; Kim K; Sondel PM; Jin WJ; Morris ZS
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade.
    Mao C; Beiss V; Ho GW; Fields J; Steinmetz NF; Fiering S
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
    Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers.
    Brinkhoff B; Ostroumov D; Heemcke J; Woller N; Gürlevik E; Manns MP; Longerich T; Zender L; Harty JT; Kubicka S; Kühnel F; Wirth TC
    Eur J Immunol; 2014 Apr; 44(4):1213-24. PubMed ID: 24338782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.
    Sheen MR; Fiering S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1524. PubMed ID: 29667346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy-Triggered In Situ Tumor Vaccination Boosts Checkpoint Blockaded Immune Response via Antigen-Capturing Nanoadjuvants.
    Xu P; Ma J; Zhou Y; Gu Y; Cheng X; Wang Y; Wang Y; Gao M
    ACS Nano; 2024 Jan; 18(1):1022-1040. PubMed ID: 38131289
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.
    Peng S; Trimble C; Alvarez RD; Huh WK; Lin Z; Monie A; Hung CF; Wu TC
    Gene Ther; 2008 Aug; 15(16):1156-66. PubMed ID: 18401437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
    Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
    Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Environment-responsive dendrobium polysaccharide hydrogel embedding manganese microsphere as a post-operative adjuvant to boost cascaded immune cycle against melanoma.
    Gao N; Huang Y; Jing S; Zhang M; Liu E; Qiu L; Huang J; Muhitdinov B; Huang Y
    Theranostics; 2024; 14(10):3810-3826. PubMed ID: 38994034
    [No Abstract]   [Full Text] [Related]  

  • 13. CXCR6 deficiency impairs cancer vaccine efficacy and CD8
    Karaki S; Blanc C; Tran T; Galy-Fauroux I; Mougel A; Dransart E; Anson M; Tanchot C; Paolini L; Gruel N; Gibault L; Lepimpec-Barhes F; Fabre E; Benhamouda N; Badoual C; Damotte D; Donnadieu E; Kobold S; Mami-Chouaib F; Golub R; Johannes L; Tartour E
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation.
    Lee SJ; Song L; Yang MC; Mao CP; Yang B; Yang A; Jeang J; Peng S; Wu TC; Hung CF
    Vaccine; 2015 Mar; 33(13):1549-55. PubMed ID: 25701675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.
    Hammerich L; Marron TU; Upadhyay R; Svensson-Arvelund J; Dhainaut M; Hussein S; Zhan Y; Ostrowski D; Yellin M; Marsh H; Salazar AM; Rahman AH; Brown BD; Merad M; Brody JD
    Nat Med; 2019 May; 25(5):814-824. PubMed ID: 30962585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
    Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
    J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy.
    Ochyl LJ; Bazzill JD; Park C; Xu Y; Kuai R; Moon JJ
    Biomaterials; 2018 Nov; 182():157-166. PubMed ID: 30121425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three steps to breaking immune tolerance to lymphoma: a microparticle approach.
    Makkouk A; Joshi VB; Lemke CD; Wongrakpanich A; Olivier AK; Blackwell SE; Salem AK; Weiner GJ
    Cancer Immunol Res; 2015 Apr; 3(4):389-98. PubMed ID: 25627654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.